Booma Yandava

Feb 1, 2024 | lesusacanada.org | Katie Schneider |Booma Yandava

Cell and gene therapy approaches for rare neurological disorders are gaining momentum and are here to stay. A recent review article authored by LES Life Sciences Sector member, Booma Yandava, M.S., MBA, Principal at Alliance Partners,  provides an overview of the advancements in cell and gene therapy (CGT) for neurological disorders, emphasizing the challenges posed by the complexity of the central nervous system and the innovative approaches being developed to overcome them.

Jan 31, 2024 | advancingrna.com | AR Welch |Advancing RNA |Louis Garguilo |Booma Yandava

Register today for the inaugural Advancing RNA, Live happening February 21st! During this discussion, we will identify where the biggest supply gaps for mRNA medicines exist today and how innovators and suppliers can work together to bridge those gaps and improve availability and quality of raw materials for improved IVT production of mRNA and LNP formulation. This digital event is free to attend thanks to the support of ThermoFisher Scientific.

Jan 18, 2024 | advancingrna.com | Booma Yandava

By Booma Yandava, M.S., MBA, Principal at Alliance Partners In the United States alone, incidences of rare diseases have surged, now numbering over 6,800 and affecting between 25 and 30 million people. This surge is paralleled by a burgeoning array of therapeutic solutions that bring significant relief to patients grappling with a wide spectrum of monogenic disorders, including those of a neurological nature.

Jan 18, 2024 | cellandgene.com | Booma Yandava

By Booma Yandava, M.S., MBA, Principal at Alliance Partners In the United States alone, incidences of rare diseases have surged, now numbering over 6,800 and affecting between 25 and 30 million people. This surge is paralleled by a burgeoning array of therapeutic solutions that bring significant relief to patients grappling with a wide spectrum of monogenic disorders, including those of a neurological nature.